

Axillary management still needed for patients with sentinel node micrometastases

Bin-Bin Cong¹⁻⁴Jin-Ming Yu^{3,4,*}Yong-Sheng Wang^{2,4,*}

¹School of Medicine and Life Sciences, University of Jinan and Shandong Academy of Medical Sciences, Jinan, Shandong, China; ²Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China; ³Department of Radiotherapy, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China; ⁴Shandong Academy of Medical Sciences, Jinan, Shandong, China

*These authors contributed equally to this work

Abstract: More attention has been paid to the axillary management over the past 50 years, and clinical practice has been changed as results of the random controlled trials. The American College of Surgeons Oncology Group Z0011 and International Breast Cancer Study Group (IBCSG) 23-01 trials provided high-level evidence to support the omission of axillary lymph nodes dissection (ALND) in sentinel lymph node (SLN)-positive patients receiving breast-conserving surgery (BCS) and adjuvant systemic treatment. In patients treated with BCS, whole breast irradiation (WBI) with tangential fields could lead to substantial axillary irradiation and control the residual tumor burden in axilla, whereas (intraoperative) partial breast irradiation has no therapeutic effect on these residual axillary metastases. In the observation group of the IBCSG 23-01 trial, 425 patients received BCS and 80 (18.8%) of them just underwent intra-operative radiotherapy. While the 10-year axillary recurrence rate was acceptable low (1.7%, 8/467) in the no ALND group, it was 4.5% (6/134) in patients without axillary management, which was significantly higher than that of 0.6% (2/333) in patients with axillary management ($P=0.0024$). Should we accept an axillary recurrence rate as high as 4.5% in patients with only SLNs micrometastases? What is the best way to control the residual tumor burden in the axilla and decrease the recurrence rate if there is no ALND? The evidence showed that both WBI after BCS (Z0011, AATRM [Agència d'Avaluació de Tecnologia i Recerca Mèdiques]) and axillary regional nodal irradiation after mastectomy/BCS OTOASOR (Optimal Treatment Of the Axilla - Surgery Or Radiotherapy), AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery) could control the regional residual tumor burden when the SLN is positive and an ALND is omitted. In the modern era, systemic therapy could further decrease the risk of local/regional recurrences. After the subanalysis of the POSNOC (POSitive Sentinel NODe: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy), SERC (Sentinelle Envahiet Randomisation du Curage), and Dutch BOOG (BORstkanker Onderzoek Groep) trials, a prediction model might be established to identify those patients who could benefit from no axillary management as a guide to clinical practice. At present, axillary management should still be required for patients with SLN micrometastases.

Keywords: breast cancer, sentinel lymph node biopsy, micrometastasis, axillary treatment

Correspondence: Yong-Sheng Wang;
Jin-Ming Yu
Shandong Cancer Hospital Affiliated to
Shandong University, 440 Jiyuan Road,
Jinan 250117, China
Tel +86 531 6762 6211;
+86 53 167 626 2141
Fax +86 531 6762 6211;
+86 53 167 626 2141
Email wangyish2008@aliyun.com;
sdyujinming@163.com

The 10-year results of American College of Surgeons Oncology Group Z0011 trial showed that cT1-2N0 breast cancer with one to two positive sentinel lymph nodes (SLNs) undergoing breast-conserving surgery (BCS) and whole breast irradiation (WBI) could omit axillary lymph nodes dissection (ALND), which provided evidence to change the clinical practice.¹ In the post-Z0011 era, Galimberti et al presented the 10-year outcomes of the International Breast Cancer Study Group (IBCSG) 23-01 trial, which provided additional evidence to support ALND omission in patients with one

or more micrometastatic (≤ 2 mm) SLNs, tumor size ≤ 5 cm, and receiving BCS and adjuvant systemic therapy.² These two clinical trials provided high-level evidence to support changes of National Comprehensive Cancer Network Guidelines since 2017³ and resulted in the “standard of care” practice in the surgical management of the axillary lymph nodes by breast surgeon.⁴ An important difference in the study design and conclusion between Z0011 and IBCSG 23-01 trials is the application of radiotherapy, in which Z0011 required that WBI should be followed by BCS but IBCSG 23-01 did not. WBI has an important effect on the axillary control in patients with positive SLNs who underwent BCS without ALND.

Although 27.3% of patients had metastatic non-SLNs in the Z0011 trial, which means a similar percentage of patients had metastatic nodes that were not surgically excised in the SNL biopsy (SLNB) alone group, the port design of WBI with tangential fields could led to substantial axillary irradiation and control the residual tumor burden in axilla.¹ The radiation field of Z0011 trial showed that some patients received high tangential irradiation fields, which means more prescribed dose delivered to lymph nodes (Table 1).^{5,6} However, (intraoperative) partial breast irradiation alone used in 27% of patients in the IBCSG 23-01 trial could not have made any therapeutic effect on the residual axillary metastases.⁷ In the observation group (ie, those with ALND omission) of IBCSG 23-01, 425 patients received BCS in which 80 (18.8%) just underwent intraoperative radiotherapy (ie, single-dose intraoperative radiotherapy with electrons in breast).² After a 10-year follow-up, 5 of these 80 patients (6.3%) with intraoperative partial breast irradiation alone had an ipsilateral axillary recurrence,^{2,7} which is totally different from that of the Z0011 trial, which had only five (0.9%) axillary relapse in the SLNB + WBI group with 10-year follow-up. In the group of ALND omission, there were 12 cases without radiotherapy in patients with BCS, 42 cases without ALND in patients with mastectomy, but 333 cases receiving axillary treatment (WBI). The total axillary recurrence rate was 1.7% (8/467), which is still acceptable low, but the axillary recurrence rate was 4.5% (6/134) in patients without axillary management, which was significantly higher than that of 0.6% (2/333) in patients with axillary management

($P=0.0024$). Should we accept an axillary recurrence rate as high as 4.5% in patients with only SLNs micrometastases?

The residual tumor burden in the axilla is a serious risk factor to lead axillary failure, and more attention should be paid. Patients with SLN micrometastases might have a low axillary disease burden, but it does not mean there is no additional axillary node involvement. In Z0011 trial, 10% of patients with SLN micrometastases were found to have macrometastases in the non-SLNs after ALND.¹ In the AATRM (Agència d’Avaluació de Tecnologia i Recerca Mèdiques) 048/13/2000 trial, 13% (15/112) of patients with SLN micrometastases identified additional positive node after ALND.⁸ Also, 13% of patients identified additional involved axillary lymph nodes after ALND in this IBCSG 23-01 study.² What is the best way to control the residual tumor burden in the axilla if there is no ALND? The evidence from clinical trials showed that both WBI after BCS (Z0011¹, AATRM⁸) and axillary regional nodal irradiation (RNI) after mastectomy/BCS OTOASOR (Optimal Treatment Of the Axilla - Surgery Or Radiotherapy),⁹ AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery)¹⁰ could control the regional residual tumor burden when the SLN is positive and an ALND is omitted.

Systemic therapy will decrease the risk of local/regional recurrences and distant metastasis in the era of molecular subtype-guided adjuvant system therapy (Figure 1).¹¹ However, with optimized systemic therapy guided by molecular subtypes, all patients with SLN micrometastases may not need ALND or axilla RNI. Currently, there are three ongoing clinical trials aiming to evaluate whether axilla management could be omitted in patients receiving modern-era therapy. The POSNOC (POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy) trial (NCT 02401685) will assess whether systemic therapy alone is noninferiority to systemic therapy plus axillary treatment (dissection or irradiation) to control the residual tumor burden in early stage breast cancer with one or two SLN macrometastases.¹² The SERC (Sentinelle Envahiet Randomisation du Curage) trial will randomly assign to observation only or ALND with positive SLN and demonstrate the noninferiority of ALND omission

Table 1 Comparison of the average dose delivered to levels I–III in the standard and the high tangential irradiation fields

Axillary nodes	Prescribed dose		95% Prescribed dose	
	Standard tangents	High tangents	Standard tangents	High tangents
Level I	66%	86%	51%	79%
Level II	44%	71%	26%	51%
Level III	31%	73%	15%	49%




Figure 1 Combined hypothetical benefit of local tumor control on survival with increasing effectiveness of systemic therapy (ST) and decreasing risk of distant metastases of the primary tumor.

Notes: Patients in the left part of the slope have high-risk disease without effective systemic therapy and are not expected to benefit from improving locoregional treatments. For patients in the right part of the slope, treatment deintensification (surgery, radiation, or systemic therapy) might be appropriate. The middle group will represent most past and current patients with breast cancer, for whom an optimum multidisciplinary approach results in the greatest benefit.

vs ALND.¹³ The Dutch BOOG (Borstkanker Onderzoek Groep) 2013-07 trial (NCT 02112682) will investigate whether completion axillary treatment can be safely omitted in SLN-positive breast cancer patients treated with mastectomy.¹⁴ After the subanalysis of these trials, a prediction model might be established to identify the patients who can benefit from no axilla management as a guide to clinical practice. In our opinion, axillary management should still be required at the present time for patients with SLN micrometastases, ie, either WBI after BCS and axillary RNI or surgical dissection after mastectomy.

Acknowledgments

We thank Xiao-Shan Cao, Chun-Jian Wang, Tong Zhao, Yan-Bing Liu, Peng Chen, Zhao-Peng Zhang, Xiao Sun, and Peng-Fei Qiu from our Breast Cancer Center. All eight of these individuals contributed to manuscript review; none received compensation for their contributions. We thank Charles M Balch from MD Anderson Cancer Center and the emeritus Editor-in-Chief of the *Annals of Surgical Oncology*, who contributed to revise the language of the manuscript.

Author contributions

All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

- Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. *JAMA*. 2017;318(10):918–926.
- Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. *Lancet Oncol*. 2018;19(10):1385–1393.
- Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: breast cancer, version 1.2017. *J Natl Compr Canc Netw*. 2017;15(4):433–451.
- Morrow M. Management of the node-positive axilla in breast cancer in 2017: selecting the right option. *JAMA Oncol*. 2018;4(2):250–251.
- Jagsi R, Chadha M, Moni J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) trial. *J Clin Oncol*. 2014;32(32):3600–3606.
- Reznik J, Cicchetti MG, Degaspe B, Fitzgerald TJ. Analysis of axillary coverage during tangential radiation therapy to the breast. *Int J Radiat Oncol Biol Phys*. 2005;61(1):163–168.
- Galimberti V, Cole BF, Zurrada S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. *Lancet Oncol*. 2013;14(4):297–305.
- Solá M, Alberro JA, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. *Ann Surg Oncol*. 2013;20(1):120–127.
- Sávolt Á, Péley G, Polgár C, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla – surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. *Eur J Surg Oncol*. 2017;43(4):672–679.

10. Rutgers E. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: 10-year results of the EORTC AMAROS trial. In: *Proceedings from the 2018 San Antonio Breast Cancer Symposium*; December 4–8; San Antonio, Texas.
11. Poortmans P. Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate. *Lancet*. 2014;383(9935):2104–2106.
12. Goyal A, Dodwell D. POSNOC: a randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. *Clin Oncol*. 2015;27(12):692–695.
13. Houvenaeghel G, Resbeut M, Boher JM. Ganglion sentinelle envahi: faut-il faire le curage ou pas? Essai randomisé SERC [Sentinel node invasion: is it necessary to perform axillary lymph node dissection? Randomized trial SERC]. *Bull Canc*. 2014;101:358–363. French.
14. van Roozendaal LM, de Wilt JH, van Dalen T, et al. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07). *BMC Canc*. 2015;15:610.

Cancer Management and Research

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>

Dovepress

a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.